Metamorphosis: How converging deep tech will propel business in the new bioeconomy
バイオテクノロジーや合成生物学などの新たなディープテックが、エキサイティングな新しいバイオエコノミーを形成しつつあります。本イノベーション解説では、その将来へのビジョンを提示し、拡張性と収益性が高く、レジリエントなバイオプロセスがビジネスと持続可能性にどのように役立つかを説明します。
バイオテクノロジーや合成生物学などの新たなディープテックが、エキサイティングな新しいバイオエコノミーを形成しつつあります。本イノベーション解説では、その将来へのビジョンを提示し、拡張性と収益性が高く、レジリエントなバイオプロセスがビジネスと持続可能性にどのように役立つかを説明します。
For many business leaders, quantum technology remains confusing and inaccessible. But it can feel more familiar when it takes its place as part of a wider system. Here Edmund Owen explains the keys to integrating quantum components into larger systems, existing value chains and business processes
Quantum technology commercial adoption will be gradual – but that doesn’t mean ambitious business leaders should adopt a wait and see approach.
The ophthalmology world is welcoming a new wave of sophisticated implant technology designed to transform diagnosis and treatment.
The digital future of ophthalmology comes with the promise of improved patient access, better quality of care, reduced workloads, optimised efficiencies and improved quality of life for patients and HCPs. There are many challenges to be overcome, not least the need to develop data, workflows and technologies in tandem. One example core example is how to best unlock successful home monitoring for ophthalmology.
A select group of thought leaders gathered at Cape Cod, by the shores of the Atlantic Ocean. They were there to collaborate, to challenge conventional thinking, and ultimately to shape a realistic vision for the future of ophthalmology.